Bookmark and Share
acyl-protein thioesterase 1 isoform 1 [Homo s.. [gi:5453722] - Target BioActivity Data
Also known as: acyl-protein thioesterase 1 isoform 1 [Homo sapiens].
Filters: All Data » Active      
Filter selected
BioActivity Outcomes:
Probe(2)
 
 
Active(852)
 
 
BioAssay Types:
Screening(830)
 
 
Confirmatory(7)
 
 
Summary(2)
 
 
Substance Types:
Chemical(854)
 
 
 
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 13    Data Row: 854   Total Pages: 43   Display: Page     
Sort: [Click the result table header to sort]
#StructureSubstanceCompoundActivityBioAssayLinks
OutcomeTypeValue [μM]
1
[SID99445332]
[CID71304779]
Summary of probe development efforts to identify inhibitors of lysophospholipase 1 (LYPLA1). [AID2202, Type: summary]
View
2
[SID99445338]
[CID56593118]
Summary of probe development efforts to identify inhibitors of lysophospholipase 1 (LYPLA1). [AID2202, Type: summary]
View
3
[SID164117611]
[CID71710938]
0.087Late stage assay provider results from the extended probe development effort to identify inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical dose-response gel-based ABPP in situ [AID743119_1, Type: confirmatory]
View
4
[SID164117614]
[CID71710927]
0.092Late stage assay provider results from the extended probe development effort to identify inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical dose-response gel-based ABPP in vitro [AID743118_1, Type: confirmatory]
View
5
[SID164117611]
[CID71710938]
0.122Late stage assay provider results from the extended probe development effort to identify inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical dose-response gel-based ABPP in vitro [AID743118_1, Type: confirmatory]
View
6
[SID164117604]
[CID71710942]
0.154Late stage assay provider results from the extended probe development effort to identify inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical dose-response gel-based ABPP in vitro [AID743118_1, Type: confirmatory]
View
7
[SID160654487]
[CID3238952]
0.21Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical dose-response gel-based ABPP [AID651990_1, Type: confirmatory]
View
8
[SID164117610]
[CID71710929]
0.225Late stage assay provider results from the extended probe development effort to identify inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical dose-response gel-based ABPP in vitro [AID743118_1, Type: confirmatory]
View
9
[SID164117613]
[CID71710939]
0.306Late stage assay provider results from the extended probe development effort to identify inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical dose-response gel-based ABPP in vitro [AID743118_1, Type: confirmatory]
View
10
[SID160654493]
[CID1081005]
Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical gel-based ABPP inhibition and selectivity [AID651988_1, Type: other]
View
11
[SID160709325]
[CID70697710]
Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1: LCMS-based Activity-Based Protein Profiling (ABPP) SILAC selectivity analysis in vitro, Set 2 [AID652018_1, Type: other]
View
12
[SID160709328]
[CID70697696]
Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1: LCMS-based Activity-Based Protein Profiling (ABPP) SILAC selectivity analysis in vitro, Set 2 [AID652018_1, Type: other]
View
13
[SID160709332]
[CID70697687]
Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1: LCMS-based Activity-Based Protein Profiling (ABPP) SILAC selectivity analysis in vitro, Set 2 [AID652018_1, Type: other]
View
14
[SID160709335]
[CID70697702]
Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1: LCMS-based Activity-Based Protein Profiling (ABPP) SILAC selectivity analysis in vitro, Set 2 [AID652018_1, Type: other]
View
15
[SID160709341]
[CID70697705]
Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1: LCMS-based Activity-Based Protein Profiling (ABPP) SILAC selectivity analysis in vitro, Set 2 [AID652018_1, Type: other]
View
16
[SID160709342]
[CID70697695]
Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1: LCMS-based Activity-Based Protein Profiling (ABPP) SILAC selectivity analysis in vitro, Set 2 [AID652018_1, Type: other]
View
17
[SID160709349]
[CID70697691]
Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1: LCMS-based Activity-Based Protein Profiling (ABPP) SILAC selectivity analysis in vitro, Set 2 [AID652018_1, Type: other]
View
18
[SID164117611]
[CID71710938]
Late stage assay provider results from the extended probe development effort to identify inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical gel-based ABPP gel filtration assay to assess inhibitor binding mode [AID743133_1, Type: other]
View
19
[SID164117611]
[CID71710938]
Late stage assay provider results from the extended probe development effort to identify inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical gel-based ABPP gel filtration assay to assess inhibitor binding mode [AID743133_2, Type: other]
View
20
[SID164117611]
[CID71710938]
Late stage assay provider results from the extended probe development effort to identify inhibitors of LYPLA1 and LYPLA2: LCMS-based cell-based Activity-Based Protein Profiling (ABPP) SILAC selectivity analysis [AID743137_1, Type: other]
View